Clinical Trial Detail

NCT ID NCT04158739
Title Flotetuzumab and Cytarabine for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Children's Oncology Group
Indications

acute myeloid leukemia

Therapies

Cytarabine + Flotetuzumab

Age Groups: adult child

No variant requirements are available.